Bristol-Myers Squibb (BMY) Gets a Hold from Erste Group
Erste Group analyst maintained a Hold rating on Bristol-Myers Squibb yesterday. The company’s shares closed today at $61.73.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol-Myers Squibb with a $62.67 average price target, a 1.52% upside from current levels. In a report released today, Wells Fargo also assigned a Hold rating to the stock with a $60.00 price target.
Based on Bristol-Myers Squibb’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.5 billion and a net profit of $1.09 billion. In comparison, last year the company earned a revenue of $12.34 billion and had a net profit of $72 million
Read More on BMY:
Disclaimer & DisclosureReport an Issue
- White House says imposing tariffs on patented pharmaceutical products
- Trump Trade: President says Iran war will still take weeks
- Trump administration readying new pharmaceutical tariffs, FT reports
- Janux announces development candidate nomination under Bristol Myers collab
- Trump Trade: U.S. not pulling assets from Strait of Hormuz yet
